EA201990023A1 - SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS - Google Patents
SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORSInfo
- Publication number
- EA201990023A1 EA201990023A1 EA201990023A EA201990023A EA201990023A1 EA 201990023 A1 EA201990023 A1 EA 201990023A1 EA 201990023 A EA201990023 A EA 201990023A EA 201990023 A EA201990023 A EA 201990023A EA 201990023 A1 EA201990023 A1 EA 201990023A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dnmt1
- relates
- treatment
- diseases associated
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к замещенным производным пиридина. В частности, изобретение относится к соединениям, соответствующим формуле (Iar)где Y, X, X, R, R, R, Rи Rопределены в описании изобретения; или их фармацевтически приемлемым солям или пролекарствам. Соединения по изобретению являются селективными ингибиторами DNMT1 и могут быть использованы при лечении злокачественного новообразования, предраковых симптомов, бета-гемоглобинопатий, серповидно-клеточного заболевания, серповидно-клеточной анемии и бета-талассемии и болезней, связанных с ингибированием DNMT1. Соответственно изобретение, кроме того, относится к фармацевтическим композициям, содержащим соединение по изобретению. Изобретение, более того, относится к способам ингибирования активности DNMT1 и лечения заболеваний, связанных с применением соединения по изобретению или фармацевтической композиции, содержащей соединение по изобретению.The invention relates to substituted pyridine derivatives. In particular, the invention relates to compounds corresponding to the formula (Iar) where Y, X, X, R, R, R, R and R are defined in the description of the invention; or their pharmaceutically acceptable salts or prodrugs. The compounds of the invention are selective inhibitors of DNMT1 and can be used in the treatment of malignant neoplasms, precancerous symptoms, beta hemoglobinopathies, sickle cell disease, sickle cell anemia and beta thalassemia and diseases associated with inhibition of DNMT1. Accordingly, the invention further relates to pharmaceutical compositions comprising a compound of the invention. The invention furthermore relates to methods of inhibiting the activity of DNMT1 and the treatment of diseases associated with the use of a compound according to the invention or a pharmaceutical composition comprising a compound according to the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662412343P | 2016-10-25 | 2016-10-25 | |
PCT/IB2017/053511 WO2017216727A1 (en) | 2016-06-13 | 2017-06-13 | Substituted pyridines as inhibitors of dnmt1 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201990023A1 true EA201990023A1 (en) | 2019-05-31 |
EA038355B1 EA038355B1 (en) | 2021-08-12 |
Family
ID=66644945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990023A EA038355B1 (en) | 2016-10-25 | 2017-06-13 | Substituted pyridines as inhibitors of dnmt1 |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA038355B1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101146010B1 (en) * | 2009-09-10 | 2012-05-16 | 서울대학교산학협력단 | COMPOSITION FOR PREVENTING OR TREATING TNF-alpha MEDIATED DISEASES |
-
2017
- 2017-06-13 EA EA201990023A patent/EA038355B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA038355B1 (en) | 2021-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502633A1 (en) | Substituted pyridines as inhibitors of dnmt1 | |
PH12016501204A1 (en) | Syk inhibitors | |
BR112015021983A2 (en) | heterocyclic compounds and their uses | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
NZ715747A (en) | Syk inhibitors | |
MX2018015709A (en) | Azabenzimidazole derivatives as pi3k beta inhibitors. | |
PH12015502425A1 (en) | Novel compounds for selective histone deacetylase inhibitors, and pharmeceutical composition comprising the same | |
EA201490228A1 (en) | NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE | |
EA201690223A1 (en) | FACTOR INHIBITORS IN THE COMPLEMENT BASED ON PIPERIDININILINDOL DERIVATIVES AND THEIR APPLICATION | |
EA201691803A1 (en) | HUMAN PLASMA KALLIKREIN INHIBITORS | |
EA201791955A1 (en) | TGF-β INHIBITORS | |
EA201690752A1 (en) | INHIBITORS G12C KRAS | |
EA201491824A1 (en) | DERIVATIVES OF BENZAMIDE FOR INHIBITION OF ABL1, ABL2 AND BCR-ABL1 ACTIVITY | |
PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
IN2014DN07283A (en) | ||
MX2015003021A (en) | Glycyrrhetinic acid derivatives with anti-inflammatory activity. | |
TN2015000574A1 (en) | Compounds and compositions as inhibitors of mek | |
NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
BR112014029439A2 (en) | salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
IN2014DN09347A (en) | ||
WO2014172188A3 (en) | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors | |
MX2015000903A (en) | Carbamate/urea derivatives. | |
MX2017013099A (en) | Methods for the treatment of inflammatory disorders. | |
EA201990023A1 (en) | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | |
UA111851C2 (en) | PIRIDASINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS |